173 related articles for article (PubMed ID: 11594583)
1. Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand.
Kadin ME; Levi E; Kempf W
Ann N Y Acad Sci; 2001 Sep; 941():59-68. PubMed ID: 11594583
[TBL] [Abstract][Full Text] [Related]
2. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma.
Schiemann WP; Pfeifer WM; Levi E; Kadin ME; Lodish HF
Blood; 1999 Oct; 94(8):2854-61. PubMed ID: 10515889
[TBL] [Abstract][Full Text] [Related]
3. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin.
Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF
Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797
[TBL] [Abstract][Full Text] [Related]
4. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression.
Levi E; Wang Z; Petrogiannis-Haliotis T; Pfeifer WM; Kempf W; Drews R; Kadin ME
J Invest Dermatol; 2000 Dec; 115(6):1034-40. PubMed ID: 11121138
[TBL] [Abstract][Full Text] [Related]
5. Localized lymphomatoid papulosis: Unilesional lymphomatoid papulosis, regional lymphomatoid papulosis, and persistent agmination of lymphomatoid papulosis.
Magro CM; Mo JH; Telang G
Clin Dermatol; 2022; 40(6):622-638. PubMed ID: 35907581
[TBL] [Abstract][Full Text] [Related]
6. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins.
Boulland ML; Wechsler J; Bagot M; Pulford K; Kanavaros P; Gaulard P
Histopathology; 2000 Feb; 36(2):136-44. PubMed ID: 10672058
[TBL] [Abstract][Full Text] [Related]
7. Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin.
Droc C; Cualing HD; Kadin ME
Cancer Control; 2007 Apr; 14(2):124-32. PubMed ID: 17387297
[TBL] [Abstract][Full Text] [Related]
8. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
9. CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression.
Mori M; Manuelli C; Pimpinelli N; Mavilia C; Maggi E; Santucci M; Bianchi B; Cappugi P; Giannotti B; Kadin ME
Blood; 1999 Nov; 94(9):3077-83. PubMed ID: 10556192
[TBL] [Abstract][Full Text] [Related]
10. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
[TBL] [Abstract][Full Text] [Related]
11. Lymphomatoid papulosis and cutaneous CD30+ lymphoma.
LeBoit PE
Am J Dermatopathol; 1996 Jun; 18(3):221-35. PubMed ID: 8806956
[TBL] [Abstract][Full Text] [Related]
12. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
13. Pathobiology of CD30+ cutaneous T-cell lymphomas.
Kadin ME
J Cutan Pathol; 2006 Feb; 33 Suppl 1():10-7. PubMed ID: 16412208
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous peripheral T-cell lymphoma, not otherwise specified, associated with lymphomatoid papulosis after a 9-year follow up: A case report.
Muraoka K; Fujimoto M; Iwahashi Y; Matsuzaki I; Yonei N; Murata SI; Jinnin M
J Dermatol; 2020 Jun; 47(6):641-645. PubMed ID: 32323371
[TBL] [Abstract][Full Text] [Related]
15. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma.
Knaus PI; Lindemann D; DeCoteau JF; Perlman R; Yankelev H; Hille M; Kadin ME; Lodish HF
Mol Cell Biol; 1996 Jul; 16(7):3480-9. PubMed ID: 8668164
[TBL] [Abstract][Full Text] [Related]
16. Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin.
Steinhoff M; Hummel M; Anagnostopoulos I; Kaudewitz P; Seitz V; Assaf C; Sander C; Stein H
Blood; 2002 Jul; 100(2):578-84. PubMed ID: 12091351
[TBL] [Abstract][Full Text] [Related]
17. Acral lymphomatoid papulosis: Report of five cases, differential diagnosis, and review.
Machan S; Juárez Martín Á; Cullen Aravena D; Haro R; Pielasinski Ú; Fuertes L; Córdoba R; Santonja C; Rodríguez-Pinilla SM; Requena L
J Cutan Pathol; 2021 May; 48(5):650-658. PubMed ID: 33269496
[TBL] [Abstract][Full Text] [Related]
18. Lymphomatoid papulosis and progression to T-cell immunoblastic lymphoma.
Morgan KW; Callen JP
J Eur Acad Dermatol Venereol; 1998 May; 10(3):280-1. PubMed ID: 9643341
[No Abstract] [Full Text] [Related]
19. Persistent agmination of lymphomatoid papulosis: an equivalent of limited plaque mycosis fungoides type of cutaneous T-cell lymphoma.
Heald P; Subtil A; Breneman D; Wilson LD
J Am Acad Dermatol; 2007 Dec; 57(6):1005-11. PubMed ID: 17919773
[TBL] [Abstract][Full Text] [Related]
20. Pseudocarcinomatous change in lymphomatoid papulosis and primary cutaneous CD30+ lymphoma: a clinicopathologic and immunohistochemical study of 6 patients.
Scarisbrick JJ; Calonje E; Orchard G; Child FJ; Russell-Jones R
J Am Acad Dermatol; 2001 Feb; 44(2):239-47. PubMed ID: 11174381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
